Exhibit 99.1 Assembly Biosciences Reports First Quarter 2025 Financial Results and Recent Updates – Ongoing clinical studies for four candidates on track with data expected in 2025, including interim Phase 1b data for long-acting helicase-primase inhibitors ABI-5366 and ABI-1179 anticipated in fall 2025 – – New data from multiple programs highlighted at ICAR, ESCMID and EASL 2025 – SOUTH SAN FRANCISCO, Calif. – May 08, 2025 – Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing inno ...